The first fallout
Taking a look at the recent dispute between the EU Commission and AstraZeneca over the ins and outs of its contract, BLM Partner and commercial litigation expert Stuart Evans, examines what this could represent for EU/UK cross-border pharma relations for PharmaTimes.
"Earlier this year we saw reports of the EU commission and AstraZeneca coming to loggerheads over vaccine roll-out across the bloc.
"At such a critical time for the industry, with all efforts focused on vaccine delivery, does this row represent one of the first major contractual fall-outs in our post-Brexit world, and what could it mean for cross-border pharma going forward?"
To read the PharmaTimes article in full, click here.